The estimated Net Worth of Bassil I Dahiyat is at least $13 Milión dollars as of 11 March 2024. Bassil Dahiyat owns over 2,741 units of Xencor Inc stock worth over $7,435,520 and over the last 11 years he sold XNCR stock worth over $1,868,634. In addition, he makes $3,731,510 as President, Chief Executive Officer a Founder and Director at Xencor Inc.
Sign up
Bassil Dahiyat XNCR stock SEC Form 4 insiders trading
Bassil has made over 18 trades of the Xencor Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 2,741 units of XNCR stock worth $64,414 on 11 March 2024.
The largest trade he's ever made was exercising 249,914 units of Xencor Inc stock on 12 March 2015 worth over $147,449. On average, Bassil trades about 32,039 units every 97 days since 2014. As of 11 March 2024 he still owns at least 351,894 units of Xencor Inc stock.
You can see the complete history of Bassil Dahiyat stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Bassil Dahiyat biography
Dr. Bassil I. Dahiyat Ph.D. serves as President, Chief Executive Officer, Founder and Director of the Company. Dr. Dahiyat has served as our President and Chief Executive Officer since February 2005 and as a member of our Board of Directors since August 1997. Dr. Dahiyat co-founded Xencor in 1997 and, from 1997 to 2003, served as our Chief Executive Officer and, from 2003 to 2005, served as our Chief Scientific Officer. Dr. Dahiyat currently serves on the board of directors of Kodiak Sciences Inc., a publicly traded company. In 2005, Dr. Dahiyat was recognized as a technology pioneer by the World Economic Forum. Additionally, Dr. Dahiyat was named one of 2003's Top 100 Young Innovators by MIT's Technology Review magazine for his work on protein design and its development for therapeutic applications and has received awards from the American Chemical Society, the Controlled Release Society and the California Institute of Technology. Dr. Dahiyat holds a Ph.D. in Chemistry from the California Institute of Technology and B.S. and M.S.E. degrees in Biomedical Engineering from Johns Hopkins University. Dahiyat's experience in the pharmaceutical industry and as one of our founders qualifies him to serve on our Board of Directors.
What is the salary of Bassil Dahiyat?
As the President, Chief Executive Officer a Founder and Director of Xencor Inc, the total compensation of Bassil Dahiyat at Xencor Inc is $3,731,510. There are no executives at Xencor Inc getting paid more.
How old is Bassil Dahiyat?
Bassil Dahiyat is 49, he's been the President, Chief Executive Officer a Founder and Director of Xencor Inc since 2015. There are 14 older and 3 younger executives at Xencor Inc. The oldest executive at Xencor Inc is Richard Ranieri, 67, who is the Independent Director.
What's Bassil Dahiyat's mailing address?
Bassil's mailing address filed with the SEC is 1200 PAGE MILL ROAD, , PALO ALTO, CA, 94304.
Insiders trading at Xencor Inc
Over the last 11 years, insiders at Xencor Inc have traded over $93,804,287 worth of Xencor Inc stock and bought 1,139,502 units worth $15,515,932 . The most active insiders traders include Capital, Llcstafford John S..., John S Iii Stafford a John S Jr Stafford. On average, Xencor Inc executives and independent directors trade stock every 23 days with the average trade being worth of $779,296. The most recent stock trade was executed by John R Desjarlais on 9 July 2024, trading 50,000 units of XNCR stock currently worth $536,500.
What does Xencor Inc do?
antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product
What does Xencor Inc's logo look like?
Complete history of Bassil Dahiyat stock trades at Xencor Inc a Kodiak Sciences Inc
Xencor Inc executives and stock owners
Xencor Inc executives and other stock owners filed with the SEC include:
-
Bassil Dahiyat,
President, Chief Executive Officer, Founder and Director -
Allen Yang,
Senior Vice President, Chief Medical Officer -
Celia Eckert,
Vice President, General Counsel, Corporate Secretary -
John Desjarlais,
Senior Vice President, Research and Chief Scientific Officer -
John Kuch,
Chief Financial Officer, Vice President -
Dr. Bassil I. Dahiyat Ph.D.,
Co-Founder, CEO, Pres & Director -
Dr. Allen S. Yang M.D., Ph.D.,
Sr. VP & Chief Medical Officer -
Dr. John R. Desjarlais,
Sr. VP of Research & Chief Scientific Officer -
Celia E. Eckert J.D.,
Sr. VP, Gen. Counsel & Corp. Sec. -
John J. Kuch,
Sr. VP & CFO -
A. Bruce Montgomery,
Lead Independent Director -
Dagmar Rosa-Bjorkeson,
Independent Director -
Kurt Gustafson,
Independent Director -
Yujiro Hata,
Independent Director -
Richard Ranieri,
Independent Director -
Kevin Gorman,
Independent Director -
Ellen Feigal,
Independent Director -
Julie Casciani,
Executive Director - Human Resources -
Kirk Rosemark,
Vice President, Regulatory Affairs and Quality Assurance -
Eric Kowack,
Vice President, Program Leadership and Strategic Alliances -
Jeremy Grunstein,
Vice President of Business Development -
Kirk Rosemark RAC,
Sr. VP of Regulatory Affairs & Quality Assurance -
Jennifer Sandoz,
VP of HR -
Charles Liles,
Associate Director and Head of Corp. Communications & Investor Relations -
John S Iii Ronin Capital, L...,
-
Paul A Foster,
Chief Medical Officer -
Barbara Klencke,
Director -
Bruce L A Carter,
Director -
Edgardo Jr Baracchini,
Chief Business Officer -
Robert Jr. Baltera,
Director -
Bart Jan Cornelissen,
SR. VICE PRESIDENT & CFO -
John S Jr Stafford,
10% owner -
Trading, Llc Ronin,
10% owner -
Lloyd A Rowland,
Sr. V.P. and General Counsel -
Atul Saran,
Director -
Harold R Werner,
Director -
Jonathan Fleming,
Director -
John S Iii Stafford,
10% owner -
Capital, Llcstafford John S...,
-
Nancy Valente,
EVP, Chief Development Officer